Amylin: The Diabetic Hormone Peptide That's Hard to Work With But Worth Improving | Research

The takeaway

Amylin is a 37-amino acid glucoregulatory peptide with proven therapeutic value (pramlintide/Symlin is FDA-approved) but its tendency to aggregate and its complex receptor system present major challenges for developing improved amylin-mimetic drugs.

37-amino acid peptide with FDA-approved mimetic
Pramlintide (Symlin) proves amylin's therapeutic value, but aggregation, solubility, and complex receptor pharmacology limit further development — insights from CGRP and hybrid peptides offer paths forward

What the researchers found

The review highlights the complex structure-function relationships of amylin and its receptors, emphasizing the challenges posed by amylin's aggregation and solubility issues. Insights from related peptides like CGRP are used to inform the design of more potent and stable amylin mimetics, including peptide hybrids.

Why it matters

Understanding amylin's structure and receptor interactions is crucial for developing better amylin-based drugs that can more effectively manage diabetes and metabolic disorders.

How the study worked

This is a literature review analyzing existing research on amylin's structure, receptor pharmacology, and related peptides to inform drug development strategies.

What this study cannot tell us

As a review, it does not present new experimental data and the evidence strength and study type are not specified, limiting direct conclusions about efficacy.

How to read the evidence

This is a review article examining structure-function relationships and drug design strategies. The existence of an FDA-approved amylin mimetic (pramlintide) provides strong validation of the therapeutic concept, though the review itself does not present new clinical data.

When this study was published

Published in 2016, this review predates the recent surge in interest in amylin-based therapeutics driven by the success of combination approaches (like amylin + GLP-1 agonists) and the broader obesity drug revolution. Some of the hybrid peptide approaches discussed have since progressed further in development.

The bigger picture

Amylin sits at the crossroads of diabetes, obesity, and neurodegeneration research. Beyond its metabolic role, amylin has been linked to Alzheimer's disease (amylin deposits found in diabetic brains) and is being explored for weight management. The development of improved amylin mimetics could yield drugs that control blood sugar, reduce body weight, and potentially address neurodegenerative conditions — making structure-function understanding critical for the field.

Questions still open

Can peptide hybrid approaches combining amylin and CGRP structural elements produce a long-acting amylin mimetic suitable for weekly dosing?
How do the aggregation-prone properties of amylin relate to the amyloid deposits found in the pancreas and brain of diabetic patients?
Would improved amylin mimetics be effective as standalone treatments for obesity, similar to the success of GLP-1 agonists?

Common questions

What is amylin and how is it different from insulin?

Amylin (also called IAPP — islet amyloid polypeptide) is a 37-amino acid hormone released together with insulin from the same pancreatic beta cells after meals. While insulin directly lowers blood sugar by helping cells absorb glucose, amylin works differently: it slows stomach emptying to prevent post-meal glucose spikes, suppresses glucagon (a hormone that raises blood sugar), and promotes satiety to reduce food intake. Both are deficient in diabetes.

Why is amylin so difficult to develop as a drug?

Native human amylin has a strong tendency to clump together into insoluble aggregates — the same process that forms toxic amyloid deposits in the pancreas of type 2 diabetes patients. This makes it nearly impossible to formulate as a stable drug. Pramlintide, the approved drug, is a modified version with three amino acid changes that reduce aggregation but still requires careful handling. Developing longer-acting, more stable versions requires deep understanding of amylin's structure-function relationships.

Read the original research

Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.

British journal of pharmacology, 173(12), 1883-98

View on PubMed ↗Publisher’s paper ↗

Citation

Bower, Rebekah L; Hay, Debbie L. (2016). Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.. British journal of pharmacology, 173(12), 1883-98. https://doi.org/10.1111/bph.13496